Kun‐Chieh Chen

1.9k citations

54 papers · 1.5k · 1 hit paper · h-index 24

Impact in

Pulmonary and Respiratory Medicine top 5%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Oncology top 10%
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers

Papers in

Pulmonary and Respiratory Medicine 36
- Lung Cancer Treatments and Mutations 33
- Lung Cancer Diagnosis and Treatment 4
Oncology 21
- Lung Cancer Research Studies 9
- Colorectal Cancer Treatments and Studies 6
- Cancer Immunotherapy and Biomarkers 5

Co-authors: Tsung‐Ying Yang (39 shared papers)Gee‐Chen Chang (38 shared papers)Kuo-Hsuan Hsu (30 shared papers)Jeng‐Sen Tseng (27 shared papers)Sung‐Liang Yu (22 shared papers)Kang‐Yi Su (17 shared papers)Yen-Hsiang Huang (19 shared papers)Shih‐Lan Hsu (6 shared papers)
Journals: Journal of Thoracic Oncology (5 papers)Scientific Reports (4 papers)Cancer Research and Treatment (3 papers)PLoS ONE (3 papers)Anti-Cancer Drugs (2 papers)
Partner nations: Taiwan United States United Kingdom

In The Last Decade

Kun‐Chieh Chen

54 papers receiving 1.4k citations

Kun‐Chieh Chen's Hit Papers

align trajectories log scale

Low-dose CT screening among never-smokers with or without a family history of lung cancer in Taiwan: a prospective cohort study 2023 · 111 citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

2023 The Lancet Respiratory Medicine

Peers

Countries citing papers authored by Kun‐Chieh Chen

Since Specialization

Citations

This map shows the geographic impact of Kun‐Chieh Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kun‐Chieh Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kun‐Chieh Chen more than expected).

Fields of papers citing papers by Kun‐Chieh Chen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kun‐Chieh Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kun‐Chieh Chen. The network helps show where Kun‐Chieh Chen may publish in the future.

Co-authors

The 25 scholars most cited alongside Kun‐Chieh Chen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Kun‐Chieh Chen Line = papers co-authored together Kun‐Chieh Chen links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 54 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Low-dose CT screening among never-smokers with or without a family history of lung cancer in Taiwan: a prospective cohort study The Lancet Respiratory Medicine ·Gee‐Chen Chang, Chao‐Hua Chiu, Chong‐Jen Yu, Yeun‐Chung Chang, Ya‐Hsuan Chang, Kuo-Hsuan Hsu, Yu‐Chung Wu, Chih-Yi Chen Hit paper breakdown →	2023	111
2	Luteolin attenuates TGF-β1-induced epithelial–mesenchymal transition of lung cancer cells by interfering in the PI3K/Akt–NF-κB–Snail pathway Life Sciences ·Kun‐Chieh Chen, Chiu-Yuan Chen, Chih-Ju Lin, Tsung‐Ying Yang, Tzu-Hsiu Chen, Li-Chen Wu, Chun‐Chi Wu	2013	90
3	High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naïve advanced EGFR-mutant lung adenocarcinoma patients Lung Cancer ·Kuo-Hsuan Hsu, Yen-Hsiang Huang, Jeng‐Sen Tseng, Kun‐Chieh Chen, Wen‐Hui Ku, Kang‐Yi Su, Jeremy J.W. Chen, Huei‐Wen Chen	2018	88
4	G enetic variants associated with longer telomere length are associated with increased lung cancer risk among never‐smoking women in Asia: a report from the female lung cancer consortium in Asia International Journal of Cancer ·Mitchell J. Machiela, Chao Agnes Hsiung, Xiao‐Ou Shu, Wei Jie Seow, Zhaoming Wang, Keitaro Matsuo, Yun‐Chul Hong, Adeline Seow	2014	82
5	Dynamic Plasma EGFR Mutation Status as a Predictor of EGFR-TKI Efficacy in Patients with EGFR-Mutant Lung Adenocarcinoma Journal of Thoracic Oncology ·Jeng‐Sen Tseng, Tsung‐Ying Yang, Chi‐Ren Tsai, Kun‐Chieh Chen, Kuo-Hsuan Hsu, Meen-Hsin Tsai, Sung‐Liang Yu, Kang‐Yi Su	2014	64
6	Complications of Therapy in Cancer Patients Journal of Clinical Oncology ·Gee‐Chen Chang, Tsung‐Ying Yang, Kun‐Chieh Chen, Ming-Chang Yin, Ren‐Ching Wang, Yung-Chiou Lin	2004	62
7	RAGE acts as an oncogenic role and promotes the metastasis of human lung cancer Cell Death and Disease ·Mei‐Chih Chen, Kun‐Chieh Chen, Gee‐Chen Chang, Ho Lin, Chun‐Chi Wu, Wei-Hsiang Kao, Chieh‐Lin Jerry Teng, Shih‐Lan Hsu	2020	57
8	Sustained activation of ERK and Cdk2/cyclin-A signaling pathway by pemetrexed leading to S-phase arrest and apoptosis in human non-small cell lung cancer A549 cells European Journal of Pharmacology ·Tsung‐Ying Yang, Gee‐Chen Chang, Kun‐Chieh Chen, Hsiao‐Wen Hung, Kuo-Hsuan Hsu, Gwo‐Tarng Sheu, Shih‐Lan Hsu	2011	54
9	Genome-wide association study of lung adenocarcinoma in East Asia and comparison with a European population Nature Communications ·Jianxin Shi, Kouya Shiraishi, Jiyeon Choi, Keitaro Matsuo, Tzu-Yu Chen, Juncheng Dai, Rayjean J. Hung, Kexin Chen	2023	49
10	The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma Cancer Research and Treatment ·Yen-Hsiang Huang, Kuo-Hsuan Hsu, Jeng‐Sen Tseng, Kun‐Chieh Chen, Chia-Hung Hsu, Kang‐Yi Su, Jeremy J.W. Chen, Huei‐Wen Chen	2018	48
11	Hypoxia can impair doxorubicin resistance of non-small cell lung cancer cells by inhibiting MRP1 and P-gp expression and boosting the chemosensitizing effects of MRP1 and P-gp blockers Cellular Oncology ·Yu‐Lun Chen, Tsung‐Ying Yang, Kun‐Chieh Chen, Chieh‐Liang Wu, Shih‐Lan Hsu, Chi‐Mei Hsueh	2016	42
12	High contrast all-solid-state electrochromic device with 2,2,6,6-tetramethyl-1-piperidinyloxy (TEMPO), heptyl viologen, and succinonitrile Solar Energy Materials and Solar Cells ·Chih‐Wei Hu, Kun‐Mu Lee, Kun‐Chieh Chen, Li-Chi Chang, Kuan-Yu Shen, Shi-Cheng Lai, Tsung-Hsien Kuo, Chih‐Yu Hsu	2011	38
13	Activity of gefitinib in advanced non-small-cell lung cancer with very poor performance status Investigational New Drugs ·Gee‐Chen Chang, Kun‐Chieh Chen, Tsung‐Ying Yang, Ming-Chang Yin, Ching-Pei Lin, Benjamin Ing-Tiau Kuo, Jeng‐Yuan Hsu	2004	36
14	ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients Scientific Reports ·Gee‐Chen Chang, Tsung‐Ying Yang, Kun‐Chieh Chen, Kuo-Hsuan Hsu, Yen-Hsiang Huang, Kang‐Yi Su, Sung‐Liang Yu, Jeng‐Sen Tseng	2020	36
15	A complementary electrochromic device based on Prussian blue and poly(ProDOT-Et2) with high contrast and high coloration efficiency Solar Energy Materials and Solar Cells ·Kun‐Chieh Chen, Chih‐Yu Hsu, Chih‐Wei Hu, Kuo–Chuan Ho	2011	36
16	Characteristics and Predictive Value of PD-L1 Status in Real-World Non–Small Cell Lung Cancer Patients Journal of Immunotherapy ·Jeng‐Sen Tseng, Tsung‐Ying Yang, Chih‐Ying Wu, Wen‐Hui Ku, Kun‐Chieh Chen, Kuo-Hsuan Hsu, Yen-Hsiang Huang, Kang‐Yi Su	2018	36
17	Association of Smoking With Patient Characteristics and Outcomes in Small Cell Lung Carcinoma, 2011-2018 JAMA Network Open ·Jeng‐Sen Tseng, Chun‐Ju Chiang, Kun‐Chieh Chen, Zhe-Rong Zheng, Tsung‐Ying Yang, Wen‐Chung Lee, Kuo-Hsuan Hsu, Yen-Hsiang Huang	2022	33
18	Retrospective study of erlotinib in patients with advanced squamous lung cancer Lung Cancer ·Jeng‐Sen Tseng, Tsung‐Ying Yang, Kun‐Chieh Chen, Kuo-Hsuan Hsu, Hsuan‐Yu Chen, Gee‐Chen Chang	2012	33
19	Pemetrexed induces both intrinsic and extrinsic apoptosis through ataxia telangiectasia mutated/p53‐dependent and ‐independent signaling pathways Molecular Carcinogenesis ·Tsung‐Ying Yang, Gee‐Chen Chang, Kun‐Chieh Chen, Hsiao‐Wen Hung, Kuo-Hsuan Hsu, Chih‐Hsiung Wu, Gwo‐Tarng Sheu, Shih‐Lan Hsu	2011	32
20	Predictive Factors of Gefitinib Antitumor Activity in East Asian Advanced Non-small Cell Lung Cancer Patients Journal of Thoracic Oncology ·Gee‐Chen Chang, Chun‐Ming Tsai, Kun‐Chieh Chen, Chong‐Jen Yu, Jin‐Yuan Shih, Tsung‐Ying Yang, Ching-Pei Lin, Jeng‐Yuan Hsu	2006	31

About Kun‐Chieh Chen

Kun‐Chieh Chen is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Cell Biology and Molecular Biology, having authored 54 papers that have together received 1.5k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (33 papers), Lung Cancer Research Studies (9 papers), Cancer Genomics and Diagnostics (6 papers), Colorectal Cancer Treatments and Studies (6 papers), Cancer Immunotherapy and Biomarkers (5 papers), Lung Cancer Diagnosis and Treatment (4 papers), Microtubule and mitosis dynamics (3 papers) and RNA modifications and cancer (3 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (679 citations), Oncology (448 citations), Cancer Research (168 citations), Aging (11 citations) and Molecular Biology (340 citations). Kun‐Chieh Chen has collaborated with scholars based in Taiwan, United States and United Kingdom. Frequent co-authors include Tsung‐Ying Yang, Gee‐Chen Chang, Kuo-Hsuan Hsu, Jeng‐Sen Tseng, Sung‐Liang Yu, Kang‐Yi Su, Yen-Hsiang Huang, Shih‐Lan Hsu, Jeremy J.W. Chen and Chun‐Chi Wu. Their work appears in journals such as Journal of Thoracic Oncology, Scientific Reports, Cancer Research and Treatment, PLoS ONE and Anti-Cancer Drugs.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Kun‐Chieh Chen

Impact in

Papers in i

In The Last Decade

Kun‐Chieh Chen

Kun‐Chieh Chen's Hit Papers

Peers

Countries citing papers authored by Kun‐Chieh Chen

Fields of papers citing papers by Kun‐Chieh Chen

All Works

About Kun‐Chieh Chen

Explore authors with similar magnitude of impact

Papers in